Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Quail-100

Phase 1

LLaguna Biotherapeutics, Inc.

Quail-100 is one of 26 therapeutic programs targeting Acute Leukemia. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

25

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute LeukemiaRecruiting

Acute LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

34 competitors in Acute Leukemia

#DrugCompanyPhaseTrials

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Dacogen

Sun Pharmaceutical Industries, Inc.

Cytoxan

BBaxter Healthcare Corporation

Venclexta

Blincyto

Xospata

Vitrakvi

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Avastin

Revuforj

SSyndax Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Acute Leukemia

NCT07573111

Clinical

Trials by Indication[1]

Acute Leukemia1 trial

An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor (TCR) αβ+ T Cell/CD-19+ B Cell-Depleted Hematopoietic Stem Cell Transplantation

Recruiting·LLaguna Biotherapeutics, Inc.·Phase 1·NCT07573111·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Quail-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Quail-100. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Laguna Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: LLaguna Biotherapeutics, Inc.

Related News